National Institute of Allergy and Infectious Diseases (NIAID)s

National Institute of Allergy and Infectious Diseases (NIAID)

184 Protocols (126 Active Accrual of new subjects, 58 Follow-up of previously enrolled subjects)

 002486-I:

A Study to Assess Safety and Tolerability, and Explore Efficacy of Leniolisib for Immune Dysregulation in Common Variable Immunodeficiency

 002480-I:

A Phase 2 Randomized Stepped Wedge Study of Emapalumab in APECED Enteritis

 002425-I:

VRC 329: A Phase I Open-Label, Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of a Quadrivalent Influenza HA Stem Vaccine VRC-FLUMOS0122-00-VP (STEMos1) with and without ALFQ Adjuvant in Healthy Adults

 002385-I:

Base Editing Hematopoietic Stem Cell and BE T Cell Gene Therapy for CD40L-HyperIgM Syndrome-Single Patient Study

 002313-I:

Use of the Esophageal String Test as a Diagnostic Screening Tool for Eosinophilic Esophagitis Among Africans with Dysphagia in Mali and the United States

 002305-I:

An Intermediate Patient Population Expanded Access Protocol for MBP091 for Patients with Marburg Virus Disease (MVD)

 002302-I:

A Pilot Prospective Study of the Esophageal String Test (EST) for the Diagnosis of Helicobacter Pylori

 002295-I:

A Study to Evaluate Immunologic and Virologic Parameters During Analytical Treatment Interruption Following Combination bNAb Therapy During Suppressive ART

 002293-I:

VRC 328: A Phase I Open-Label Clinical Trial to Evaluate the Dose, Safety, Tolerability, and Immunogenicity of Mosaic Hexavalent Influenza Vaccine VRC-FLUMOS0116-00-VP (FluMos-v2) with and without ALFQ Adjuvant in Healthy Adults

 002288-I:

Phase 1 Study of the Safety of an Epstein-Barr Virus (EBV) gH/gL/gp42-Ferritin Nanoparticle Vaccine With or Without gp350-Ferritin in Healthy Adults With or Without EBV Infection

 002273-I:

Phase 1/2 Base-Edited Hematopoietic Stem/Progenitor Cell X-Linked Severe Combined Immunodeficiency Gene Therapy

 002223-I:

An Open-Label, Single-Arm Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Leniolisib for Immune Dysregulation in Primary Immunodeficiency Disorders

 002211-I:

Lenacapavir Intensification to Disrupt HIV Reservoirs in Virologically Suppressed People with HIV Receiving Antiretroviral Therapy

 002206-I:

Intermediate Expanded Access Program for NT-I7 (efineptakin alfa) in Patients With Autosomal Recessive Genetic Deficiency of Interleukin-7

 002176-I:

A Pilot Study to Evaluate the Safety and Tolerability of Baricitinib in Patients with Job s Syndrome with Lupus-like Disease and/or Atopic Dermatitis

 002062-I:

Modeling Host-Pathogen Interaction Using Lymphoid Organoids

 001979-I:

A Pilot Phase 2 Study of the Safety and Efficacy of Dupilumab as Add-on Therapy for Hypereosinophilic Syndrome with Partial Clinical Response to Eosinophil-Depleting Biologic Agents

 001976-I:

A Study to Assess Safety and Tolerability, and Explore Efficacy of Leniolisib for Immune Dysregulation in Primary Immunodeficiency Disorders

 001970-I:

Phase 1 Study of Induced Blood-Stage Malaria in Healthy Malaria-Naive Adults to Assess the Safety and Infectivity of Plasmodium Vivax Challenge Agent and Evaluate Transmission in Mosquito Feeding Assays

 001957-I:

Intermediate Patient Population Expanded Access Protocol for MBP134 for Patients with Sudan Virus Disease (SVD)

 001928-I:

A Biorepository of Multiple Allergic Diseases (MADREP) With Longitudinal Follow-up

 001899-I:

Hemophagocytic Lymphohistiocytosis (HLH) Evaluation and Research of Clinical, ImmUnoLogic and TranscriptomE Study

 001867-I:

A Phase 1 Study of Repeat PET/CT Imaging in People with CAPS and Anakinra-Induced Amyloidosis Using Amyloid-Reactive Peptide 124I-AT-01 (124I-p5+14, Iodine-124I-Evuzamitide) to Measure Changes in Organ-Specific Amyloid Load

 001854-I:

An Open-Label Study of Zemaira (Alpha 1-Trypsin Inhibitor) in Subjects with Eosinophilic Esophagitis

 001824-I:

A Phase 2a Study of the ITK Inhibitor Soquelitinib to Reduce Lymphoproliferation and Improve Cytopenias in Autoimmune Lymphoproliferative Syndrome (ALPS)-FAS Patients

 001716-I:

Analysis of Autoinflammation in Chronic Granulomatous Disease Patients Undergoing Hematopoietic Cell Transplant or Gene Therapy RDCRN - PIDTC 6908

 001706-I:

A Controlled Human Infection Study of Orally Administered Trichuris Trichiura Eggs in Naive Adults

 001677-I:

A Phase 2b, Double-Blind, Randomized, Placebo-Controlled Trial of Cardamom and Topical Roseomonas in Atopic Dermatitis

 001658-I:

Adoptive T Lymphocyte Administration for Chronic Norovirus Treatment in Immunocompromised Hosts

 001580-I:

Phase 1/2 Trial of Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-linked Chronic Granulomatous Disease

 001562-I:

A Phase I/II, Non-Randomized, Open-Label Study of pCCLCHIM-p47 (Lentiviral Vector Transduced CD34+ Cells) in Patients with p47 Autosomal Recessive Chronic Granulomatous Disease (AR-CGD)

 001511-I:

Detection and Characterization of Neurologic Manifestations of Inborn and Acquired Errors of Immunity

 001146-I:

A Repository to Study Host-Microbiome Interactions in Health and Disease

 001043-I:

Evaluating the Genetics and Immunology of Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Cervical Adenitis (PFAPA) Syndrome and Other Tonsil Disorders

 001037-I:

A Randomized Placebo-controlled Study to Evaluate the Safety and Effects of Repeated Doses of 3BNC117-LS and 10-1074-LS on Persistent Viral Reservoirs in People Living with HIV and on Suppressive Antiretroviral Therapy

 000977-I:

Phase I/II Study using Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease with an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined with Cytokine (IL-6, +/- IFN-gamma) Antagonists

 000906-I:

A Phase 2 Randomized Cross-Over Design Study of the Early Metabolic Effects of Dolutegravir or Tenofovir Alafenamide in Healthy Volunteers

 000866-I:

Phase 1/2 Open-label Trial of Safety and Zoster Immunogenicity Evaluation for people with HIV with CD4 counts Under and Above 300 and Healthy Volunteers following Shingrix Vaccination (ZEUS)

 000861-I:

A Phase 2 Open-Label Study to Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients with Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata

 000821-I:

An Open-Label, Single-Arm, Phase 1/2 Dose-Escalation Trial of Long-Acting Recombinant Human IL-7 (NT-I7, Efineptakin-Alpha) for Idiopathic CD4 Lymphopenia

 000809-I:

A Pilot Study of Fecal Microbiota Transplantation for Chronic Granulomatous Disease-Associated Colitis

 000707-I:

Respiratory Virus Sampling and Repository

 000688-I:

Longitudinal Observations of Vaccine Responses to SARS-CoV-2 and other Emerging Infectious Diseases

 000392-I:

Metabolic Profiling of Immune Responses in Immune-Mediated Diseases

 000331-I:

Investigating the Human Immune Response to Ixodes scapularis Tick Bites

 000291-I:

Observational Digital Biomarker Discovery in Respiratory Virus Challenge Studies

 000281-I:

Pilot Assessment To Find Evidence of Gastric Motility Abnormalities in Eosinophilic Gastric Disorders

 000256-I:

Natural History of Systemic and Nasal Mucosal Immunity to Influenza and SARS-CoV-2 in Adults after Vaccination

 000226-I:

Belimumab and Rituximab Compared to Rituximab Alone for the Treatment of Primary Membranous Nephropathy

 000201-I:

Pediatric SARS-CoV-2 and MIS-C Long-term Follow-up

 000186-I:

Part B- Phase I/II, Non-Randomized, Single site study, Open-label Study of G1XCGD (Lentiviral Vector Transduced CD34+ Cells) in Patients with X-Linked Chronic Granulomatous Disease

 000064-I:

A Phase 1/2 Open-label Study to Evaluate the Safety and Efficacy of Tofacitinib for Chronic Granulomatous Disease with Inflammatory Complications

 22-I-0001:

NADPH Oxidase Correction in mRNA transfected Granulocyte-enriched Cells in Chronic Granulomatous Disease (CGD)

 21-I-0029:

Natural History, Epidemiology and Pathogenesis of Severe HPV-Related Diseases (Neptune)

 19-I-0140:

A Phase 1 Evaluation of the Safety of Belimumab in People with Idiopathic CD4 Lymphopenia and Autoantibodies (Phoebe)

 19-I-0133:

Paradoxical Tuberculosis Reactions in Patients without HIV Infection

 19-I-0093:

Collection of Human Biospecimens for Basic and Clinical Research into Globin Variants

 19-I-0069:

Phase I Open-Label Study of Safety and Immunogenicity of AD4-HIV Envelope Vaccine Vectors in Healthy Volunteers

 19-I-0053:

Prospective Study to Identify Food-Specific and Component IgE Threshold Levels that Predict Food Allergy in Patients with Elevated Total Serum IgE Levels and Atopic Dermatitis

 19-I-0022:

A Prospective, Multicenter Study to Compare and Validate Endoscopic, Histologic, Molecular, and Patient-Reported Outcomes in Pediatric and Adult Patients with Eosinophilic Esophagitis (EoE), Gastritis (EoG), Enteritis (EoN) and Colitis (EoC)

 18-I-0128:

Send-In Sample Collection to Achieve Genetic and Immunologic Characterization of Primary Immunodeficiencies

 18-I-0101:

Sample Collection From Healthy Volunteers for Assay Optimization

 18-I-0041:

Investigating the Mechanistic Biology of Primary Immunodeficiency Disorders

 17-I-0122:

NIAID Centralized Sequencing Protocol

 17-I-0101:

An Open-Label, Proof of Concept Study of Vorinostat for the Treatment of Moderate-to-Severe Crohn's Disease and Maintenance Therapy with Ustekinumab

 17-I-0083:

Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)

 17-I-0016:

Studies of the Natural History, Pathogenesis, and Outcome of Autoinflammatory Diseases (NOMID/CAPS, DIRA, CANDLE, SAVI, NLRC4-MAS, Still's-like Diseases, and Other Undifferentiated Autoinflammatory Diseases)

 16-I-0039:

Screening of Healthy Volunteers for Investigational Antimalarial Drugs, Malaria Vaccines, and Controlled Human Malaria Challenge

 15-I-0162:

Natural History and Genetics of Food Allergy and Related Conditions

 15-I-0154:

Long-Term Observation of Hemagglutinin and Neuraminidase Inhibition Antibody Titers After Influenza Challenge

 14-I-0206:

Novel Genetic Disorders of the Immune System

 14-I-0146:

The Pathogenesis and Genetics of Disseminated or Refractory Coccidioidomycosis

 14-I-0124:

PET Imaging and Lymph Node Assessment of IRIS in Persons With AIDS

 14-I-0020:

Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

 13-I-0157:

The Natural History of GATA2 Deficiency and Related Disorders

 11-I-0187:

The Natural History and Pathogenesis of Human Fungal Infections

 11-I-0183:

Screening for LID Clinical Studies Unit Healthy Volunteer Protocols

 11-I-0164:

VRC 500: Screening Volunteers for Clinical Trials of Investigational Products and Licensed Products Evaluated for Research Purposes

 11-I-0109:

Viral Infections in Healthy and Immunocompromised Hosts

 11-I-0007:

Lentiviral Gene Transfer for Treatment of Children Older Than 2 Years of Age with X-Linked Severe Combined Immunodeficiency

 10-I-0216:

Studies of Disorders with Increased Susceptibility to Fungal Infections

 10-I-0197:

Admission and Management of Occupational or Other Exposures to Biodefense/Bioterrorism Agents or to Epidemic/Emerging Infectious Diseases

 10-I-0195:

Natural History of Tuberculosis

 10-I-0109:

VRC 900: Evaluation of Tissue-Specific Immune Responses in Adults 18 Years of Age and Older

 10-I-0014:

The Natural History of Severe Viral Infections and Characterization of Immune Defects

 09-I-0200:

A Phase I Study of MozobilTM in the Treatment of Patients with WHIMS

 09-I-0133:

Establishing Fibroblast-derived Cell Lines from Skin/Tissue Biopsies of Patients with Immunodeficiency or Immunodysregulation Disorders

 09-I-0102:

Etiology, Pathogenesis, and Natural History of Idiopathic CD4+ Lymphocytopenia

 09-I-0032:

Comprehensive Multimodal Analysis of Patients with Neuroimmunological Diseases of the CNS

 09-I-0030:

Clinical and Immunologic Monitoring of Patients with Known or Suspected HIV Infection

 08-I-0221:

Analysis of HIV-1 Replication During Antiretroviral Therapy

 07-I-0033:

Screening Protocol for Detection and Characterization of Infections and Infection Susceptibility

 06-I-0015:

Screening Protocol for Genetic Diseases of Lymphocyte Homeostasis and Programmed Cell Death

 05-I-0213:

Screening and Baseline Assessment of Patients with Abnormalities of Immune Function

 04-I-0286:

A Longitudinal Study of Familial Hypereosinophilia (FE): Natural History and Markers of Disease Progression

 04-I-0266:

Collection of Data and Samples from Healthy Donors for Use in Translational Research

 03-I-0263:

VRC 200: A Multicenter Specimen Collection Protocol to Obtain Human Biological Samples for Research Studies

 02-I-0286:

Efficacy of Tyrosine Kinase Inhibition in Reducing Eosinophilia in Patients with Myeloid and/or Steroid-Refractory Hypereosinophilic Syndrome

 02-I-0277:

Regulation of the Proliferation and Survival of Normal and Neoplastic Human Mast Cells

 02-I-0202:

Leukapheresis Procedures to Obtain Plasma and Lymphocytes for Research Studies on Antiretroviral Naive HIV-1 Research Participants

Next 84 Protocols